CSL stock trades 3.73 percent above its EUR 113.10 target

Published on 10/16/2026 at 15:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CSL's AGM is set for October 27, 2026, with four resolutions. CSL stock costs EUR 117.48 on October 16, 2026 at 3:34 p.m. CEST.

Analyst view and calendar

Five analyst houses put the 12-month consensus target at EUR 113.10 on October 14, 2026.
CSL will hold its annual general meeting on October 27, 2026.
CSL stock costs EUR 117.48 at Lang & Schwarz on October 16, 2026 at 3:34 p.m. CEST.
CSL had a market capitalization of AUD 92.2 billion on October 16, 2026.

CSL, AU000000CSL8, Illustration mit AI erstellt.

Five analyst houses put the 12-month consensus target for CSL at EUR 113.10 on October 14, 2026, according to Boerse Express. With CSL stock at EUR 117.48 at Lang & Schwarz on October 16, 2026 at 3:34 p.m. CEST, the consensus target stood 3.73 percent below the euro price. The target is the strongest valuation marker for investors today.

Analyst target leaves limited room

The consensus target was EUR 113.10, while the analyst range extended from EUR 112.48 to EUR 133.10, according to Boerse Express on October 14, 2026. Four of five houses carried a Buy view and one carried a Hold view. The target range therefore spans a broad EUR 20.62, even though the median target sits below the Lang & Schwarz quotation.

Annual meeting brings four votes

CSL's next dated corporate event is its annual general meeting on October 27, 2026. The official notice lists four resolutions, including the election or re-election of three directors and the advisory vote on the remuneration report, as reported in the company's CSL Limited notice dated September 17, 2026.

Price position and valuation

CSL's Australian listing traded at AUD 192.20 on October 16, 2026 at 4:10 p.m. AEDT, up 2.84 percent from AUD 186.90. The session range was AUD 187.32 to AUD 192.59, while the 52-week range was AUD 90.00 to AUD 222.47. Market capitalization stood at AUD 92.2 billion and the reported price-to-earnings ratio was minus 25.22 on the same quotation.

Comparison with peers

CSL (ASX, AUD): 2.84 percent, P/E minus 25.22, market capitalization AUD 92.2 billion.
Baxter International (NYSE, USD): 0.64 percent, P/E minus 12.71, market capitalization USD 13.4 billion.
Takeda Pharmaceutical (NYSE, USD): 1.00 percent, P/E 55.47, market capitalization USD 62.1 billion.

What the calendar adds

The AGM gives shareholders a defined near-term date for questions on the year ended June 30, 2026 and on the leadership transition. The price picture combines a quotation near the upper end of its Australian range with a consensus target below the current euro price.